HC Wainwright Analysts Increase Earnings Estimates for CRDF

Cardiff Oncology, Inc. (NASDAQ:CRDF – Free Report) – Equities research analysts at HC Wainwright increased their FY2026 EPS estimates for Cardiff Oncology in a research note issued to investors on Monday, November 16th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.55) for the year, up from their previous estimate of ($0.56). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for Cardiff Oncology’s Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.29) EPS.

A number of other equities analysts also recently issued reports on CRDF. William Blair downgraded Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded Cardiff Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 5th. Finally, Weiss Ratings upgraded Cardiff Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 9th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cardiff Oncology currently has a consensus rating of “Hold” and an average target price of $7.50.

Get Our Latest Stock Report on CRDF

Cardiff Oncology Price Performance

NASDAQ CRDF opened at $0.85 on Wednesday. The business’s fifty day moving average price is $1.03 and its 200-day moving average price is $1.34. Cardiff Oncology has a 1-year low of $0.71 and a 1-year high of $3.31.

Cardiff Oncology (NASDAQ:CRDF – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. The business had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.08 million. Cardiff Oncology had a negative net margin of 6,736.49% and a negative return on equity of 111.80%.

Institutional Trading of Cardiff Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Cardiff Oncology during the 2nd quarter valued at $1,265,000. GoalVest Advisory LLC bought a new position in Cardiff Oncology in the 3rd quarter worth $832,000. Hsbc Holdings PLC bought a new position in Cardiff Oncology in the 2nd quarter worth $37,000. Bank of New York Mellon Corp bought a new position in Cardiff Oncology in the 2nd quarter worth $210,000. Finally, Glenview Trust Co bought a new position in Cardiff Oncology in the 2nd quarter worth $56,000. 16.29% of the stock is owned by hedge funds and other institutional investors.

Cardiff Oncology Company Profile

(Get Free Report)

Cardiff Oncology is a clinical-stage biotechnology company focused on developing cancer treatments. Its lead drug candidate, onvansertib, is an oral, selective inhibitor of polo-like kinase 1 (PLK1), a protein involved in cell division that the company is investigating as a target in cancer therapy. The company is studying onvansertib in combination with existing treatments for several cancers, including metastatic colorectal cancer and acute myeloid leukemia. These programs remain in clinical development, and the candidate is not an approved treatment.

Recommended Stories

Earnings History and Estimates for Cardiff Oncology (NASDAQ:CRDF)

Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.